2008
DOI: 10.1016/j.jaci.2008.06.015
|View full text |Cite
|
Sign up to set email alerts
|

A cumulative dose study of levalbuterol and racemic albuterol administered by hydrofluoroalkane-134a metered-dose inhaler in asthmatic subjects

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
5
0
1

Year Published

2009
2009
2016
2016

Publication Types

Select...
5
2

Relationship

0
7

Authors

Journals

citations
Cited by 13 publications
(6 citation statements)
references
References 11 publications
0
5
0
1
Order By: Relevance
“…The selectivity of levosalbutamol theoretically maximizes the bronchodilating effects while minimizing systemic side effects such as tachycardia 25 and hypokalemia. 26 Small trials have shown mixed results, with some trials showing benefit in pulmonary function, 27,28 reduction in hospital admission rates, 29 and reduced side effects 26,30 ; whereas other studies have shown no difference. 30,31 Levosalbutamol is considerably more expensive than the conventional racemic mixture, and current guidelines do not recommend using one over the other.…”
Section: First-line Treatmentmentioning
confidence: 99%
“…The selectivity of levosalbutamol theoretically maximizes the bronchodilating effects while minimizing systemic side effects such as tachycardia 25 and hypokalemia. 26 Small trials have shown mixed results, with some trials showing benefit in pulmonary function, 27,28 reduction in hospital admission rates, 29 and reduced side effects 26,30 ; whereas other studies have shown no difference. 30,31 Levosalbutamol is considerably more expensive than the conventional racemic mixture, and current guidelines do not recommend using one over the other.…”
Section: First-line Treatmentmentioning
confidence: 99%
“…We read with interest the results of Tripp et al, 1 who used a cumulative dose-response protocol to compare hydrofluoroalkane (HFA) formulations of either levalbuterol or racemic albuterol in asthmatic subjects. They found that plasma levels of R-albuterol were lower after levalbuterol (ie, R-enantiomer) than after racemic (ie, RS) albuterol in conjunction with reduced heart rate but not potassium response when levalbuterol was administered at a 1:2 mg dose ratio.…”
Section: Levalbuterol Kineticsmentioning
confidence: 99%
“…In 2008, Tripp et al looked at the safety outcomes of levalbuterol HFA metered dose inhaler (MDI) and racemic albuterol HFA MDI in asthmatic patients in a randomized, modified-blind, active-controlled, multicenter, 2-way crossover study. 9 The 49 participating subjects were randomized to 16 cumulative doses of levalbuterol (45 µg per dose) or racemic albuterol (90 µg per dose) administered over a 2-hour period. After having a 7-day washout period, the subjects were then crossed over to the other treatment.…”
Section: Introductionmentioning
confidence: 99%